Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three YearsCompared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 C
PRINCETON, N.J.--(BUSINESS WIRE)--?Bristol Myers Squibb?(NYSE: BMY) today announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with?Opdivo?(nivolumab) plus?Yervoy?(ipilimumab) compared to platinum-based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM), regardless of histology.
With a minimum follow-up of three years (35.5 months):
- Among patients treated with?Opdivo?plus?Yervoy, 23% were alive at three years, compared to 15% of patients treated with chemotherapy.
- Treatment with the dual immunotherapy combination continued to show a reduction in the risk of death (Hazard Ratio [HR] 0.73; 95% Confidence Interval [CI]: 0.61 to 0.87), and improvement in median overall survival (OS), the trial?s primary endpoint, vs. chemotherapy (18.1 months vs. 14.1 months, respectively).
- 28% of patients who responded to?Opdivo?plus?Yervoy?remained in response at three years compared to no patients (0%) in the chemotherapy arm.
- Those treated with the dual immunotherapy combinationhad a median DOR of 11.6 months, compared to 6.7 months with chemotherapy.
- Objective response rate (ORR) in patients treated with the combination was comparable to chemotherapy (39.6% vs. 44.0%, respectively).